The Lancet Regional Health - Southeast Asia
Virological and metabolic outcomes after switching to dolutegravir or rilpivirine in virologically suppressed adults with HIV in Thailand: an open-label, randomised, controlled, non-inferiority trial
By Rattagan Kajeekul, Narisa Ruenroengbun, Sirichai Wiwatrojanagul and 5 others.
Abstract
Summary: Background: Dolutegravir (DTG)-based antiretroviral therapy is widely recommended; however, weight gain and metabolic effects remain a concern. Rilpivirine (RPV) is a potential switch option for virologically suppressed individuals with HIV receiving efavirenz (EFV)-based treatment. We aimed to compare the virological and metabolic outcomes after switching from TDF/FTC/EFV to TDF/3TC/DTG or TDF/FTC plus RPV.